DK3104872T3 - Paricalcitol til anvendelse ved behandling af inflammatorisk - Google Patents

Paricalcitol til anvendelse ved behandling af inflammatorisk Download PDF

Info

Publication number
DK3104872T3
DK3104872T3 DK15702156.9T DK15702156T DK3104872T3 DK 3104872 T3 DK3104872 T3 DK 3104872T3 DK 15702156 T DK15702156 T DK 15702156T DK 3104872 T3 DK3104872 T3 DK 3104872T3
Authority
DK
Denmark
Prior art keywords
inflammatoric
paricalcitol
treatment
Prior art date
Application number
DK15702156.9T
Other languages
Danish (da)
English (en)
Inventor
Rivera Miguel Giovanni Uriol
Original Assignee
Rivera Miguel Giovanni Uriol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rivera Miguel Giovanni Uriol filed Critical Rivera Miguel Giovanni Uriol
Application granted granted Critical
Publication of DK3104872T3 publication Critical patent/DK3104872T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK15702156.9T 2014-02-11 2015-01-16 Paricalcitol til anvendelse ved behandling af inflammatorisk DK3104872T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201430177A ES2472040B1 (es) 2014-02-11 2014-02-11 Uso de paricalcitol en el tratamiento de la anemia inflamatoria
PCT/EP2015/050817 WO2015121022A1 (en) 2014-02-11 2015-01-16 Use of paricalcitol in the treatment of inflammatory anaemia

Publications (1)

Publication Number Publication Date
DK3104872T3 true DK3104872T3 (da) 2019-06-17

Family

ID=51205045

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15702156.9T DK3104872T3 (da) 2014-02-11 2015-01-16 Paricalcitol til anvendelse ved behandling af inflammatorisk

Country Status (16)

Country Link
US (1) US11464791B2 (enExample)
EP (1) EP3104872B1 (enExample)
JP (1) JP2017512753A (enExample)
KR (1) KR20160113664A (enExample)
CN (1) CN106061498B (enExample)
AR (1) AR099330A1 (enExample)
AU (1) AU2015217956B2 (enExample)
CA (1) CA2938057A1 (enExample)
DK (1) DK3104872T3 (enExample)
ES (2) ES2472040B1 (enExample)
IL (1) IL247207B (enExample)
MX (1) MX365096B (enExample)
PT (1) PT3104872T (enExample)
RU (1) RU2016131412A (enExample)
UY (1) UY35989A (enExample)
WO (1) WO2015121022A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102504090B1 (ko) * 2020-08-05 2023-02-24 경상국립대학교병원 조영제-유발 신독성 예방 또는 치료용 약학 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1583539A2 (en) 2003-01-13 2005-10-12 Cedars-Sinai Medical Center Paricalcitol as a chemotherapeutic agent
CA2563874A1 (en) * 2004-04-23 2005-11-03 Cambridge Antibody Technology Limited Erythropoietin protein variants
WO2008086025A2 (en) * 2007-01-10 2008-07-17 Edison Pharmaceuticals, Inc. Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity
CN102772364B (zh) * 2011-05-13 2015-12-02 重庆华邦制药有限公司 帕立骨化醇的脂肪乳及其制剂和制备方法

Also Published As

Publication number Publication date
ES2472040B1 (es) 2015-07-01
AU2015217956B2 (en) 2019-04-04
CN106061498B (zh) 2019-12-06
AR099330A1 (es) 2016-07-13
ES2472040R1 (es) 2014-09-18
WO2015121022A1 (en) 2015-08-20
ES2472040A2 (es) 2014-06-27
EP3104872A1 (en) 2016-12-21
US20160367571A1 (en) 2016-12-22
EP3104872B1 (en) 2019-03-13
MX2016010104A (es) 2017-01-06
MX365096B (es) 2019-05-22
IL247207A0 (en) 2016-09-29
PT3104872T (pt) 2019-06-11
ES2728158T3 (es) 2019-10-22
RU2016131412A (ru) 2018-03-15
IL247207B (en) 2020-02-27
US11464791B2 (en) 2022-10-11
CN106061498A (zh) 2016-10-26
CA2938057A1 (en) 2015-08-20
JP2017512753A (ja) 2017-05-25
KR20160113664A (ko) 2016-09-30
AU2015217956A1 (en) 2016-08-25
UY35989A (es) 2015-03-27

Similar Documents

Publication Publication Date Title
DK3492632T3 (da) Metoder til behandling af lithiumholdige materialer
DK3166976T3 (da) Anti-pd-l1-kombinationer til behandling af tumorer
DK3192902T3 (da) Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3718507T3 (da) Anordninger til behandling af nedre ekstremitetsvaskulatur
DK3556775T3 (da) Anti-lag-3 antistoffer til behandling af hæmatologiske maligniteter
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3286311T3 (da) Fremgangsmåde til behandling af maligniteter
DK3221359T3 (da) Fremgangsmåder til tumorbehandling ved anvendelse af CD3XCD20-bispecifikt antistof
DK3193929T3 (da) Behandlingsregimer ved anvendelse af anti-nkg2a-antistoffer
DK3096741T3 (da) Fremgangsmåde til fremstillingen af hybridosomer
DK3134530T3 (da) Behandling af hyperbilirubinæmi
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3072835T3 (da) Fremgangsmåde til fremføring
DK3172227T3 (da) Molekyler der selektivt aktiverer regulatoriske t-celler til behandlingen af autoimmune sygdomme
DK3256853T3 (da) Forudsigelse af t-celleepitoper, der er egnede til vaccination
DK3143025T3 (da) Forbindelser til behandling af spinal muskelatrofi
DK3185957T3 (da) Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis
DK3174858T3 (da) Fremgangsmåde til fremstilling af pyrazoler
DK3261726T3 (da) Sammensætning til behandling af acne
DK3148529T3 (da) Forbindelser til behandling af hjernecancer
DK3456330T3 (da) Cortexolon-17alpha-valerat til anvendelse ved behandling af tumorer
DK3125898T3 (da) Farmakofor til trail-induktion
DK3164716T3 (da) Fremgangsmåde til diagnosticering af neurodegenerative sygdomme
DK3233813T3 (da) Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser
DK3122308T3 (da) Indretning til behandling af smerte